- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
NICE says ‘yes’ to degarelix for men with prostate cancer and spinal metastases
1 July 2016 • Author: Victoria White, Digital Content Producer
This announcement comes after a review process lasting over 3 years, and follows NICE’s most recent draft Appraisal Consultation Document (ACD) published in June 2015, which recommended against the use of degarelix within its marketing authorisation for treating advanced hormone-dependent prostate cancer.
Ferring UK’s General Manager, Steve Howson, commented: “NICE’s decision represents a significant step forward, and is very good news for men living with advanced hormone-dependent prostate cancer, who are in need of rapid control of their condition. This has been a long process but throughout these last 3 years we have maintained our firm belief that degarelix can have a significant impact on patients’ lives. We are delighted that our belief will now be realised across the UK.”
A “critical” decision
Testosterone-lowering therapy is considered a primary treatment for prostate cancer. In clinical studies, degarelix demonstrated an immediate reduction in testosterone levels upon initial use, achieving clinically significant levels within 3 days. Maintenance therapy with degarelix led to long-term testosterone suppression for up to 5 years. The therapy has shown significantly longer progression-free survival, compared with luteinising hormone-releasing hormone (LHRH) agonists, an existing hormonal therapy. Furthermore, clinical studies have demonstrated that men treated with degarelix have a significantly reduced risk of cardiovascular disease, fewer musculoskeletal events and a lower incidence of urinary tract events than those treated with LHRH agonists. Treatment with the therapy has also demonstrated a more rapid reduction in prostate-specific antigen (PSA); a significant reduction in the risk of PSA progression, compared with existing hormonal therapies; and a better control of serum alkaline phosphatase (S-ALP), which is indicative of tumour activity within bones.
Commenting on the approval of the therapy, Heather Blake, Director of Support and Influencing at Prostate Cancer UK, said: “Today’s decision is critical for those men who already have cancer in their spine when they begin hormone therapy treatment, because degarelix is the only one of these treatments which can provide immediate reduction of cancer in the bone and stop this awful condition taking hold.
“The approval of degarelix, not only for men with symptoms of spinal cord compression but also those at risk, will give thousands the best possible chance to avoid the onset of spinal cord compression and all that it brings with it. This final decision has been a long time coming, and we strongly encourage local commissioners and the manufacturer to work together to get the necessary agreements in place as swiftly as possible, so men in England and Wales can start to receive the treatment without delay.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics